757 related articles for article (PubMed ID: 32167160)
1. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
[TBL] [Abstract][Full Text] [Related]
2. Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy.
de Roest RH; Mes SW; Poell JB; Brink A; van de Wiel MA; Bloemena E; Thai E; Poli T; Leemans CR; Brakenhoff RH
Clin Cancer Res; 2019 Dec; 25(23):7256-7265. PubMed ID: 31439582
[TBL] [Abstract][Full Text] [Related]
3. Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma.
Peng CH; Liao CT; Ng KP; Tai AS; Peng SC; Yeh JP; Chen SJ; Tsao KC; Yen TC; Hsieh WP
Oncotarget; 2015 Aug; 6(23):19891-906. PubMed ID: 26087196
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
[TBL] [Abstract][Full Text] [Related]
5. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and chemotherapeutic implications of a novel four-gene pyroptosis model in head and neck squamous cell carcinoma.
Yuan P; Jiang S; Wang Q; Wu Y; Jiang Y; Xu H; Jiang L; Luo X
PeerJ; 2024; 12():e17296. PubMed ID: 38756442
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab.
Patel U; Pandey M; Kannan S; Samant TA; Gera P; Mittal N; Rane S; Patil A; Noronha V; Joshi A; Patil VM; Prabhash K; Mahimkar MB
Br J Cancer; 2020 Dec; 123(12):1757-1766. PubMed ID: 32939054
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Correlation of an Autophagy-Related Gene Signature in Patients with Head and Neck Squamous Cell Carcinoma.
Yang C; Mei H; Peng L; Jiang F; Xie B; Li J
Comput Math Methods Med; 2020; 2020():7397132. PubMed ID: 33456497
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in head and neck squamous cell carcinoma.
He F; Chen Z; Deng W; Zhan T; Huang X; Zheng Y; Yang H
Int Immunopharmacol; 2021 Sep; 98():107789. PubMed ID: 34130150
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
Gulati S; Desai J; Palackdharry SM; Morris JC; Zhu Z; Jandarov R; Riaz MK; Takiar V; Mierzwa M; Gutkind JS; Molinolo A; Desai PB; Sadraei NH; Wise-Draper TM
Cancer; 2020 Jan; 126(2):354-362. PubMed ID: 31626727
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data.
Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Di Stefano J; Knepley C; Limaye S; Mamtani R; Wisnivesky J; Damjanov N; Langer CJ; Cohen RB; Sigel K
Cancer; 2019 Feb; 125(3):406-415. PubMed ID: 30341983
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy.
van der Heijden M; Essers PBM; Verhagen CVM; Willems SM; Sanders J; de Roest RH; Vossen DM; Leemans CR; Verheij M; Brakenhoff RH; van den Brekel MWM; Vens C
Radiother Oncol; 2020 Jun; 147():186-194. PubMed ID: 32413532
[TBL] [Abstract][Full Text] [Related]
13. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.
Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G
Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115
[TBL] [Abstract][Full Text] [Related]
14. Unraveling most abundant mutational signatures in head and neck cancer.
Plath M; Gass J; Hlevnjak M; Li Q; Feng B; Hostench XP; Bieg M; Schroeder L; Holzinger D; Zapatka M; Freier K; Weichert W; Hess J; Zaoui K
Int J Cancer; 2021 Jan; 148(1):115-127. PubMed ID: 32930393
[TBL] [Abstract][Full Text] [Related]
15. Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer.
Huang L; David O; Cabay RJ; Valyi-Nagy K; Macias V; Zhong R; Wenig B; Feldman L; Weichselbaum R; Spiotto MT
Clin Cancer Res; 2019 Mar; 25(6):1795-1808. PubMed ID: 30573692
[TBL] [Abstract][Full Text] [Related]
16. Identification novel prognostic signatures for Head and Neck Squamous Cell Carcinoma based on ceRNA network construction and immune infiltration analysis.
Zhou H; He Y; Li L; Wu C; Hu G
Int J Med Sci; 2021; 18(5):1297-1311. PubMed ID: 33526991
[No Abstract] [Full Text] [Related]
17. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R; Trad Wadsworth J; Higgins K; Beitler JJ; Ramalingam SS; Owonikoko TK; Khuri FR; Shin DM; Behera M; Saba NF
Head Neck; 2019 May; 41(5):1490-1498. PubMed ID: 30835900
[TBL] [Abstract][Full Text] [Related]
18. Prognostic microRNA signatures derived from The Cancer Genome Atlas for head and neck squamous cell carcinomas.
Wong N; Khwaja SS; Baker CM; Gay HA; Thorstad WL; Daly MD; Lewis JS; Wang X
Cancer Med; 2016 Jul; 5(7):1619-28. PubMed ID: 27109697
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
20. A novel comprehensive immune-related gene signature as a promising survival predictor for the patients with head and neck squamous cell carcinoma.
Fang R; Iqbal M; Chen L; Liao J; Luo J; Wei F; Wen W; Sun W
Aging (Albany NY); 2021 Apr; 13(8):11507-11527. PubMed ID: 33867351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
